Results

Total Results: 522 records

Showing results for "tissue".

281. 08 Functional Limitations Potential High Impact 2012-12-10 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/08_functional_limitations_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - Nasha ™ /Dx (Solesta ® ; Oceana Therapeutics, Inc., Edison, NJ), is a biocompatible tissue- bulking … generate it, being smaller in size than plasmin to potentially allow greater penetration of epiretinal tissues … Nasha ™ /Dx, Solesta ® (Oceana Therapeutics, Inc., Edison, NJ), is a biocompatible tissue-bulking … Basing their opinions on preliminary results, they thought the tissue-bulking agent would not always … to generate it; smaller size than plasmin, potentially allowing greater penetration of epiretinal tissues

282. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-update_research-protocol.pdf
     May 07, 2010 - Components of this system can be identified in many tissues.

283. Laboratory Tests | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/laboratory-tests

284. Transparency of Reporting Requirements: Tympanostomy Tubes (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/transparency-tympanostomy_research-protocol.pdf
     September 02, 2016 - Granulation tissue 5. Premature extrusion 6.

285. Anal Cancer | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/anal-cancer

286. Genetic Disorders | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/genetic-disorders

287. Retinal Detachment | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/retinal-detachment

288. Cannabis-2023-Surv-Rep-4-Table-E-5 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-table-E-5.xlsx
     January 01, 2023 - disorders: 7.1% (24/337) vs. 6.2% (21/337), RR 1.14 (95% CI 0.65 to 2.01) Musculoskeletal and connective tissue

289. Cannabis-2022-Surv-Rep-4-Table-F5 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-table-F5.xlsx
     January 01, 2022 - disorders: 7.1% (24/337) vs. 6.2% (21/337), RR 1.14 (95% CI 0.65 to 2.01) Musculoskeletal and connective tissue

290. Evidence Summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-evidence-summary-2022-update_0.pdf
     January 01, 2022 - Purpose Chronic pain is defined as pain lasting longer than 3 to 6 months or past normal time for tissue

291. Carbohydrates | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/carbohydrates

292. Data Points 15: Breast Cancer Diagnostic Workup: Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dcis-prognostic-tests_research.pdf
     August 22, 2012 - evidence supports the applicability of this knowledge to DCIS.3 In invasive breast cancer, removed tissue … oophorectomy.7 Lymph node testing is used to detect whether the cancer has progressed beyond the breast tissue

293. Prostate Cancer | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/prostate-cancer

294. Diabetic Eye Problems | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/diabetic-eye-problems

295. Breast Reconstruction | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/breast-reconstruction

296. Meningitis | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/health-topics/meningitis

297. Rapid Response: Efficacy of Dental Services for Reducing Adverse Events in Those Receiving Chemotherapy for Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/rapid-response-chemotherapy-dental.pdf
     July 01, 2023 - osteonecrosis incidence, in that patients did not receive bisphosphonates or other drugs that target bone tissue … had meaningful impacts on the integrity of the oral mucosa and (in some cases) the integrity of bony tissue … care on the rates of osteonecrosis among patients who will undergo cancer treatments that target bony tissue … odontogenic and periodontal infections, extractions, periodontal care, and removal of sources of tissue

298. Effectiveness of Noninvasive Diagnostic Tests for Breast Abnormalities Appendices (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-abnormalities-tests_appendixes.pdf
     May 23, 2005 - 75.2%) 80.7% (76.0% to 84.7%) 3.44 (3.16 to 3.74) 0.36 (0.29 to 0.45) 276 Dense breast tissue … 75.3%) 80.8% (73.7% to 86.3%) 3.23 (2.84 to 3.67) 0.38 (0.28 to 0.52) 304 Fatty breast tissue … 78.1%) 86.1% (80.6% to 90.6%) 2.84 (2.71 to 2.97) 0.17 (0.12 to 0.24) 79 Dense breast tissue … 83.3% (65.3% to 94.4%) 2.14 (1.88 to 2.43) 0.23 (0.10 to 0.53) 106 Mostly fatty breast tissue … to 88.6%) 1.77 (1.67 to 1.87) 0.13 (0.05 to 0.33) 32 Postiive by FNA, dense breast tissue

299. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_disposition-comments.pdf
     June 01, 2010 - treatment for ICH. 15 The problem is brain hemorrhage, which often continues to expand and destroy brain tissue … most effective ways to ensure that a hemostatic agent targets the source of bleeding in the brain tissue … not all of the ICH literature is in the setting of intracerebral hemorrhage (bleeding into the brain tissue … Different anatomic mechanisms of injury often result in the final common pathways of severe tissue

300. genetic-testing-developmental-disabilities-protocol-140930 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/genetic-testing-developmental-disabilities_research-protocol.pdf
     September 30, 2014 - where appropriate), cross-contamination during sample processing, inclusion of normal, non-diseased tissue … with the diseased tissue of interest, tissue from a source additional to the desired sample (e.g.,